A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture
- Author
- LEWIS, A. M1 ; KRAUSE, P1 ; PEDEN, K1
[1] Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food And Drug Administration, Bethesda, MD, United States - Conference title
- Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development
- Conference name
- Evolution of Cell Substrates Used in the Manufacture of Biological's. Workshop (Rockville, Maryland 1999-09-07)
- Author (monograph)
- BROWN, Fred (Editor)1 ; LEWIS, Andrew (Editor)2 ; KRAUSE, Philip (Editor)2 ; PEDEN, Keith (Editor)2
Center for biologics Evaluation and Research (CBER), Bethesda, MD (Funder/Sponsor)
International Association for Biologicals (IABs), International (Funder/Sponsor)
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, United States (Funder/Sponsor)
National Vaccine Program Office (NVPO) (Funder/Sponsor)
World Health Organization (WHO), Geneva, Switzerland (Funder/Sponsor)
[1] Plum Island Disease Center, Greenport, New York, United States
[2] Division of Viral Products, CBER/FDA/DHHS, 29 Lincoln Drive, Bethesda, MD 20892 - Source
Developments in biologicals. 2001, Vol 106, pp 513-535 ; ref : 61 ref
- Publisher
- Karger, Basel
/
Karger, Freiburg
/
Karger, Paris
- Publication country
- Switzerland
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Tumeur maligne Utilisation Vaccin
- Keyword (en)
- Malignant tumor Use Vaccine
- Keyword (es)
- Tumor maligno Utilización Vacuna
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology
- Discipline
- Microbiology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 14167218
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Developments in biologicals\";s:9:\"\u0000*\u0000stitle\";s:9:\"Dev. biol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"513\";s:8:\"\u0000*\u0000epage\";s:3:\"535\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1424-6074\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"LEWIS\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"KRAUSE, P\";i:1;s:8:\"PEDEN, K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development\";s:8:\"\u0000*\u0000title\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Developments in biologicals\";s:9:\"\u0000*\u0000stitle\";s:9:\"Dev. biol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"513\";s:8:\"\u0000*\u0000epage\";s:3:\"535\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1424-6074\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"LEWIS\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"KRAUSE, P\";i:1;s:8:\"PEDEN, K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development\";s:8:\"\u0000*\u0000title\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Developments in biologicals\";s:9:\"\u0000*\u0000stitle\";s:9:\"Dev. biol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"513\";s:8:\"\u0000*\u0000epage\";s:3:\"535\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1424-6074\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"LEWIS\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"KRAUSE, P\";i:1;s:8:\"PEDEN, K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development\";s:8:\"\u0000*\u0000title\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Developments in biologicals\";s:9:\"\u0000*\u0000stitle\";s:9:\"Dev. biol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"513\";s:8:\"\u0000*\u0000epage\";s:3:\"535\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1424-6074\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"LEWIS\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"KRAUSE, P\";i:1;s:8:\"PEDEN, K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development\";s:8:\"\u0000*\u0000title\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Developments in biologicals\";s:9:\"\u0000*\u0000stitle\";s:9:\"Dev. biol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"513\";s:8:\"\u0000*\u0000epage\";s:3:\"535\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1424-6074\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"LEWIS\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"KRAUSE, P\";i:1;s:8:\"PEDEN, K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development\";s:8:\"\u0000*\u0000title\";s:128:\"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
